Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers – Fundraising led by Cambrian BioPharma and Solve FSHD –– Company expands pipeline with new program, VTA-120, for the treatment of facioscapulohumeral muscular dystrophy (FSHD) – Baltimore, MD, October 12, 2022 – Vita Therapeutics, a cell engineering company harnessing …
SOLVE FSHD Invests US $1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy GAITHERSBURG, Maryland and VANCOUVER, British Columbia – September 29, 2022 – miRecule, Inc., an innovator of next-generation RNA therapeutics, and SOLVE FSHD, a venture-philanthropy organization catalyzing the pace of innovation to accelerate a cure for facioscapulohumeral …
VANCOUVER, B.C., Sept 21, 2022 – SOLVE FSHD, a venture-philanthropy organization catalyzing the pace of innovation to accelerate a cure for FSHD, announced today an investment of US$3 million in Altay Therapeutics; a company focused on developing lifesaving therapies by targeting disease-causing transcription factors. This investment will support Altay Therapeutics’ unique approach to finding an …
SOLVE FSHD Provides Funding to n-Lorem for a Collaboration to Expand Understanding of FSHD2, a Rare Form of Muscular Dystrophy SOLVE FSHD contributes more than $1 million to n-Lorem to support research efforts to inform a therapeutic strategy for FSHD2 nano-rare patients SAN DIEGO, Calif., Sept. 9, 2022, n-Lorem, a nonprofit foundation, today announced that Solve …
VANCOUVER, B.C. – Following SOLVE FSHD’s recent acclaimed launch, the organization is pleased to formally announce the appointment of Dr. Eva Chin as the Executive Director. SOLVE FSHD’s Founder, Chip Wilson, has personally committed USD100 million to find a cure for facioscapulohumeral muscular dystrophy (FSHD), a rare disease he was diagnosed with at the age …
VANCOUVER, B.C. – SOLVE FSHD, the venture-philanthropy organization founded by entrepreneur Chip Wilson, announces its financial support to the FSHD Canada Foundation’s strategic investment of US$1.2M in biomarker grant funding to facilitate biomarker research in facioscapulohumeral muscular dystrophy (FSHD). The FSHD Canada Foundation acknowledges the generous support of SOLVE FSHD towards funding these grants. The …